No retraction, correction or concern found when last checked on Oct 25, 2026.
Messing up disorder: how do missense mutations in the tumor suppressor protein APC lead to cancer?
David P Minde, Zeinab Anvarian, Stefan GD Rüdiger and 1 more
Molecular Cancer · 2011 · Review
Abstract
Mutations in the adenomatous polyposis coli (APC) tumor suppressor gene strongly predispose to development of gastro-intestinal tumors. Central to the tumorigenic events in APC mutant cells is the uncontrolled stabilization and transcriptional activation of the protein β-catenin. Many questions remain as to how APC controls β-catenin degradation. Remarkably, the large C-terminal region of APC, which spans over 2000 amino acids and includes critical regions in downregulating β-catenin, is predicted to be natively unfolded. Here we discuss how this uncommonly large disordered region may help to coordinate the multiple cellular functions of APC. Recently, a significant number of germline and somatic missense mutations in the central region of APC were linked to tumorigenesis in the colon as well as extra-intestinal tissues. We classify and localize all currently known missense mutations in the APC structure. The molecular basis by which these mutations interfere with the function of APC remains unresolved. We propose several mechanisms by which cancer-related missense mutations in the large disordered domain of APC may interfere with tumor suppressor activity. Insight in the underlying molecular events will be invaluable in the development of novel strategies to counter dysregulated Wnt signaling by APC mutations in cancer.
Full text
From PubMed Central, U.S. National Library of Medicine, as current on Oct 25, 2026. Paragraph numbers are ours, so an answer can point at one.
Introduction
Adenomatous polyposis coli (APC) is a key tumor suppressor gene that acts as a gatekeeper of intestinal epithelial homeostasis by restraining cytoplasmic cellular levels of β-catenin, the central activator of transcription in the Wnt signaling pathway. At the molecular level, APC co-scaffolds a multiprotein destruction complex, composed of the tumor suppressor Axin and the serine-threonine kinases GSK3β and CK1, which promotes the phosphorylation and subsequent ubiquitin-mediated degradation of β-catenin. A Wnt-induced signal at the cell surface impedes the function of the APC-Axin complex, leading to the stabilization and nuclear import of β-catenin, followed by the formation of nuclear β-catenin/TCF complexes that activate target gene transcription. Besides regulating proliferation and differentiation through Wnt/β-catenin signaling, APC controls multiple β-catenin-independent fundamental cellular processes. These include cell adhesion and migration, organization of the cytoskeleton, spindle formation and chromosome segregation. The crucial role of APC in fundamental developmental cellular processes is illustrated by the embryonic lethality of homozygous Apc-knock-out mutations. In this review, we focus on how the remarkable lack of structure in the large central domain of APC may facilitate its tumor suppressor function in the Wnt/β-catenin cascade. Furthermore, by classification and localization of known cancer-related APC missense mutations, we uncover different mutational spectra of germline and somatic missense mutations along the APC protein sequence, suggesting variation in functional relevance and mechanisms. We discuss how these missense mutations in the large unstructured region of APC may predispose to cancer.
The large central domain of APC contains multiple domains that control Wnt signaling
APC is a 312 kDa protein composed of 2843 amino acid residues. It carries multiple designated segments with which it coordinates its multiple cellular functions (Figure 1A). The large central region of APC, spanning residues L1021-D2059, has been implicated in the downregulation of β-catenin. It contains four 15aa repeat and seven 20aa repeat segments involved in β-catenin binding. The 15aa repeat region also binds the transcriptional co-repressor CtBP1 and CtBP2, which prevents nuclear β-catenin activity and facilitates APC oligomerization and. Interspersed with the 20aa β-catenin binding repeats three short recognition motifs, composed of the highly conserved LxECIxSAMP sequence (called SAMP motif), constitute binding sites for Axin. The remarkably large number of β-catenin binding sites in the APC protein has instigated an area of intense research to search for the mechanistic role of the APC β-catenin binding repeats in the destruction complex.
Each 15aa repeat of APC binds to the structural groove formed by the armadillo repeats 5-10 on the surface of β-catenin in a phosphorylation-independent manner. The 20aa repeats require phosphorylation of a consensus SXXSSLSXLS motif to convert into tight binding sites for β-catenin. In addition, two negatively charged residues in the N-terminal flanking regions of the core 20aa repeats make significant contact with β-catenin by forming 2 salt bridges with K435 and K312 of β-catenin. Once bound, one single phosphorylated 20aa repeat plus N-terminal flanking sequence of APC occupies almost the entire groove that spans from armadillo repeats 1 to 12 on the β-catenin surface. The bound conformation of one extended 20aa repeat is nearly identical to that of other functional binding partners of β-catenin, TCF and E-cadherin, indicating that these proteins cannot bind β-catenin simultaneously.
Unlike their equal organization in binding motifs, individual 15aa and 20aa repeats in APC vary considerably in their binding affinities for β-catenin, with the tightest binding site being the phosphorylated third 20aa repeat (Kd 1.5 nM). Remarkably, the highly conserved second 20aa repeat completely lacks binding affinity for β-catenin, even in the phosphorylated state, likely due to the absence of some of the conserved residues in the N-terminal region flanking the core 20aa sequence. Phosphorylated APC competes with Axin for binding to β-catenin, whereas unphosphorylated does not. Based on these findings, various models have been proposed on the mechanism by which phosphorylation of the 20aa repeats in APC may regulate β-catenin recruitment and turnover. In a first model, both the 15aa repeats of APC and the β-catenin binding domain in Axin bind β-catenin side by side to induce β-catenin phosphorylation by GSK3β. As soon as the third 20aa repeat of APC is phosphorylated it will bind phospho-β-catenin thereby releasing Axin from the complex. This would facilitate the discharge and degradation of phospho-β-catenin and allow a new phosphorylation cycle to occur. In a second model, β-catenin first binds phosphorylated APC with high affinity. Subsequent dephosphorylation of APC is then required to weaken the interaction between APC and β-catenin, allowing transfer of β-catenin to Axin and phosphorylation by Axin-associated GSK3β. This model is opposed by recent findings that demonstrate a crucial role of APC in protecting phosho-β-catenin from dephosphorylation by PP2A. As a consequence, APC would stay tethered to phospho-β-catenin and directly deliver it to the E3 ligase β-TrCP for ubiquitination. In a third model, phosphorylation of APC accommodates the fluctuation in β-catenin levels in the cell in conditions of presence versus absence of a Wnt signal. During active Wnt signaling, abundant levels of β-catenin will be dealt with by rapid and transient interactions between β-catenin and nonphosphorylated APC. In the absence of a Wnt signal, low levels of β-catenin will be tightly bound and slowly released by phosphorylated APC.
Each of the above models were challenged by a recent study in which the roles of the 20aa and 15aa repeats were addressed systematically through the functional analysis of a large number of APC variants in human cells and flies. Importantly, separate roles of APC in the cytoplasmic retention and destruction of β-catenin were uncovered, involving selective APC regions. The affinities of individual β-catenin binding repeats in APC were uncovered to be of lesser importance in the destruction of β-catenin than anticipated in previous models. Instead, the β-catenin binding repeats act in concert to mediate retention of the β-catenin protein in the cytoplasm, thus preventing its activity in the nucleus. Strikingly, the second 20aa repeat which lacks affinity for β-catenin, as well as the conserved sequence B/CID, located in between the second and third 20aa repeat (Figure 1A), perform critical roles in the APC-mediated destruction of β-catenin. How these regions control APC activity and whether this involves binding of co-factors remains to be solved.
Further experiments are needed to demonstrate if the repeat regions act simultaneously or sequentially and determine how these events are regulated by APC phosphorylation as well as by the second 20aa repeat and sequence B in the process of β-catenin destruction.
The central domain of APC is intrinsically disordered
Strikingly, APC lacks sequence conservation outside the small repetitive β-catenin- and axin-binding regions and sequence B. This led us to investigate the structural properties of APC in more detail using nine established algorithms to predict secondary structure and disorder. Each of the algorithms consistently indicate the presence of an exceptionally large intrinsically disordered region from F800 to V2843 in APC (Figure 1B), yielding a stretch of 2000 residues with an extended, flexible conformation (Figure 2). The reliability of those algorithms is well established as illustrated using β-catenin and Axin as example proteins, for which we can compare bioinformatics results with the experimentally verified structure (Figure 1D). The disorder prediction algorithms for β-catenin confirm unfolded N- and C-terminal segments flanking the folded, helical core of the protein. Indeed, for these regions crystallographic studies failed to detect regular structure. For the Wnt pathway tumor suppressor Axin, we experimentally confirmed the intrinsically disordered nature of the functionally important central region, thus confirming the predictions derived of various algorithms. The prediction data for APC are supported by Far-UV CD spectra and NMR studies on various purified short APC fragments that include the β-catenin interacting 15aa and 20aa repeat regions in the unbound state. In addition, the middle and C-terminal regions of APC, but not its N-terminus, were sensitive to proteolytic degradation, confirming a lack of globular domains in this part of the protein. While short disordered sequences are common features in human proteins, such as e. g. activation loops in kinases, a continous stretch of 2000 amino acids length is rather unique in the human proteome.
Intrinsically disordered regions in proteins are rapidly gaining interest because of their intimate connection to signaling networks and their growing link to human disease. Disordered regions of over 30 residues in length are 5- to 15-fold enriched in higher eukaryotic proteomes (30%) relative to eubacteria (6%) and archaea (2%), respectively, which is believed to reflect the use of disordered domains in higher order eukaryotic signaling networks. Moreover, 79% of cancer-associated proteins contain disordered regions of 30 residues or longer. Among these are key tumor suppressor proteins like p53, Axin, BRCA1 and the pro-apoptotic protein ASPP2.
What could be the functional advantage of such a long, extended, unstructured region for APC? Strikingly, intrinsically disordered regions are often strongly modified by e.g. phosphorylation or acetylation, which implies a relation between their dynamic appearance and regulation by posttranslational modification. Indeed, such modifications can fine-tune protein-protein interactions and activity of the protein complex. Another aspect of the extended nature of intrinsically disordered domains are simultaneous interactions with multiple binding partners with high specificity. For BRCA1, the breast cancer tumor suppressor protein, over 50 binding partners were reported, the majority of which bind to the unstructured central domain. In remarkable contrast to BRCA1 and other disordered proteins, the unstructured central domain of APC mainly provides repetitive binding sites for two Wnt pathway binding partners, β-catenin and Axin.
A possible reason for this unusual property of APC might be related to the tight regulation of its activities. The main function of the central domain of APC is to downregulate cytoplasmic β-catenin levels with the assistance of Axin and its associated kinases CK1 and GSK3β. We propose that the long, flexible conformation of APC helps to sift through the cytoplasm for β-catenin substrate. The possibility to capture a β-catenin molecule is enhanced by large contact surface created by the extended peptide repeats that may allow one APC molecule to bind up to ten β-catenin molecules in the phosphorylated state (Figure 1), using four 15aa and six functional 20aa repeats. The presence of several binding sites, some of which are regulated, controls affinity for β-catenin by an avidity effect. This effect is further increased by dimerization of APC.
Disordered proteins occupy a significantly larger volume than folded proteins. Assuming that the conformational ensemble of APC was random, the 2000 disordered C-terminal APC residues would occupy the volume of a particle with a diameter of 45 nm. This can be calculated based on the experimentally determined radius of gyration for disordered proteins, multiplied with square root of 6. Disordered proteins, however, differ from folded proteins by being able to easily adapt their shape to external influence. The structural flexibility can be illustrated by a gedankenexperiment: assuming that the backbone of one amino acid covers 3 Å in a fully extended conformation, 2000 amino acids could potentially stretch to maximally 0.6 μm when forced to do so. Its extended structure would place APC among the longest non-polymeric proteins located to the cytosol. Stretching of APC can be enforced e.g. binding to cofactors. Indeed, β-catenin was found to significantly extend the part of APC that is bound to it. Extrapolation from the conformation exhibited by the disordered APC fragment in complex with β-catenin as it was found by X-Ray crystallography, would stretch APC to around 0.2 μm. In comparison, the folded 510 amino acid long armadillo repeat region of β-catenin, which also exhibits an extended structure, is fixed at a defined length of just about 10 nm (Figure 2). The actual length of APC is most likely between those extremes and might be modulated by its interaction partners.
Disorder secures specificity of complex formation
In several reported cases, binding of interacting proteins induces (partial) folding or secondary structure formation of disordered regions. Templates for folding include other proteins, nucleic acids, membranes, or small molecules. The conformation that is adopted by one intrinsically disordered region may differ significantly depending on the binding partner. Thus, disordered domains may provide significant binding plasticity. Therefore, disordered sequences are enriched in signaling proteins such as APC that are part of complex protein interaction networks.
Alternatively, the disordered regions of APC may not undergo significant conformational changes but instead remain in extended conformation to provide in abundant and transient contacts with their binding partners. As binding of a disordered protein to a partner restricts its dynamics, the interaction will involve an entropic penalty, which folded proteins do not pay. As a result, disordered proteins can display highly specific interactions of relatively low affinity as compared to protein-protein interactions involving folded proteins. These interactions frequently depend on electrostatic interactions tuned by posttranslational modifications (e.g. phosphorylation) that create changes in net charge of the binding regions. Crystal structures obtained from short APC peptide fragments in complex with β-catenin reveal that the phosphorylated 20aa peptide of APC does not acquire structure but remains largely extended while bound to β-catenin. The extended conformation allows merely 15 residues of APC (A1485-G1499) to bind to the entire groove on the β-catenin Arm repeat surface. In contrast, the SAMP repeat segments, predicted to lack secondary structure in the unbound state, adopt a helical conformation upon binding to the Axin RGS domain. Clearly, the central domain of APC uses different binding modes in its interaction with β-catenin and Axin.
How may APC exploit the properties of its unstructured domains and secure specificity of their function? Like many other scaffolding proteins, APC acts in multiple independent cellular pathways at different subcellular locations and within different protein complexes. If conformation of an unstructured domain depends on its binding partners the protein will mold to adjust to the pathway in which it functions together with signaling partners in the complex. Moreover, it can be envisioned that allosteric mechanisms propagate structure or signals to flanking domains, further enforcing this functionally adoptive mechanism by determining which distant binding partners are allowed to join in the protein complex. To what extend such molecular mechanisms apply for APC remains to be determined.
Mutations in APC cause cancer
The fact that mutations in APC strongly predispose to colon cancer is well established. Individuals carrying a truncating APC allele suffer from familial adenomatous polyposis (FAP), an autosomal dominant disorder characterized by hundreds to thousands of colorectal adenomas, some of which progress to cancer. Moreover, mutations in APC are found in around 80% of sporadic colonic tumors. The molecular events in FAP patients are phenocopied in the small intestine of mouse models in which APC is truncated after the N-terminal Armadillo repeat region, thus lacking domains involved in β-catenin downregulation. The high frequency of gastro-intestinal tumor formation in these mice results from loss of the wild-type allele (LOH) and the following stabilization and accumulation of transcriptionally active nuclear β-catenin.
APC does not, however, act as a classical tumor suppressor. Careful comparison of mutations in both Apc alleles in tumors, levels of Wnt signaling and severity of disease in both humans and mice has led to a model in which gene dosage effects generate a defined window of enhanced Wnt signaling which leads to polyp formation in the intestine. Combinations of 'milder' Apc mutations, associated with weaker enhancement of Wnt signaling, rather lead to tumors in extra-intestinal tissues. In this model, the nature of the germline mutation in Apc determines the type of somatic mutation mutation that occurs in the second allele. As a consequence, the resulting Wnt pathway activity is 'just right' for tumor formation.
The main focus of research in this area has been on the effects of truncating mutations in Apc. In these cases, large portions of the protein, including defined regulatory domains, are lost. Recent studies, using optimized technology to identify base pair alterations, indicate that in a significant number of cases, however, germline as well as sporadic single amino acid substitutions (missense mutations) in Apc predispose to development of colorectal adenomas. Notably, a significant number of APC missense mutations were reported in tumors originating from various tissues (listed in additional file 1, Table S1, including references therein). Moreover, missense mutations in APC were linked to worse disease outcome in invasive urothelial carcinomas, suggesting functional relevance of point mutated APC protein in the development of extra-intestinal tumors. Most of these mutations remain functionally uncharacterized although for some missense mutant APC proteins Wnt signaling activating properties were demonstrated. The molecular basis by which these mutations interfere with the function of APC remains unresolved.
Molecular consequences of missense mutations in the disordered domain of APC
Long, unstructured regions are likely more apt to resist the effects of point mutations than a folded protein. In the large disordered region of APC, mutational resistance is expected to be further enhanced by multiplication of important interaction sites for partner proteins. A large number of germline and somatic missense mutations in APC however link to various forms of cancer and are identified in a scattered pattern throughout the APC protein (Figure 1C and additional file 1, Table S1). Moreover, the somatic missense mutation frequency is strongly enriched in the central Wnt regulatory MCR region that is also frequently hit by truncating mutations. Of note, the increased frequency in missense mutations could be the result of the sequencing bias of many studies in which the MCR region was selectively sequenced to identify mutations in APC. Remarkably, the majority of reported missense mutations in APC MCR are located outside the essential 15aa and 20aa repeat regions and their flanking N-terminal regions required for binding β-catenin (Figure 3 and additional file 1, Table S1). How can these seemingly subtle changes in an unstructured domain have such dramatic consequences? We propose several mechanisms by which missense mutations can dysregulate APC function.
(i) Altered protein interaction surface. Many of the reported missense mutations change side chain charges which might have direct implications for the formation of protein-protein interaction interfaces (additional file 1, Table S1). The single known binding partner of the MCR region is β-catenin but, surprisingly, most of the cancer-related mutations are outside the β-catenin binding repeats. Possibly, the mutated residues belong to non-redundant, so far unknown protein-protein interaction sites, although the lower conservation of these regions would render this option less likely.
(ii) Changes in secondary structure formation. Missense mutations may alter the ability of APC to adopt structure when bound to its interaction partners in the destruction complex. This would be of importance for local helix formation of APC SAMP-repeat regions upon binding Axin. Indeed, missense mutations that locate to these regions and introduce residues that reduce helix stability (Gly, Val) were reported as germline mutations in cases of adenomatous polyposis coli (Figure 3 and additional file 1, Table S1).
(iii) Posttranslational modifications. Point mutations may interfere with posttranslational modifications of APC. For instance, mutations in APC may alter recognition sites for responsible kinases such as CK1 and GSK3β. These kinases do not directly dock onto APC but rather are positioned towards their substrate residues by binding to Axin in the complex. Mutations within close proximity of target Ser residues in the 20aa repeats may interfere with phosphorylation of these motifs. Alternatively, mutations may hamper the protecting function of APC towards PP2A-mediated dephosphorylation of phospho-β-catenin and/or the delivery of β-catenin to β-TrCP. Interference with this role of APC may lead to rapid dephosphorylation and stabilization of β-catenin. It is currently unknown what regions of APC are involved in these consecutive steps in β-catenin degradation and whether or not this requires extended or folded APC configuration. This information will be essential to determine whether missense mutations may interfere with this function of APC.
(iv) Dynamics of conformational equilibrium. Natively unfolded sequences may adopt a specific three dimensional conformation upon binding of a partner protein. This may include a specific spatial arrangement of the repeat regions in APC. Point mutations outside those regions could prevent the required formation of a specific three-dimensional structure and, thereby, inhibit APC's usual mode of action. Hypothetically, mutations may also influence long-range intramolecular signaling. Examples of allosteric regulation of protein signaling are rapidly emerging. Binding to or modification of one end of an protein elicits a signal that is communicated through the protein to trigger a response at a remote site, although it would be less obvious how such signal transmission may work in an unfolded segment.
If and how these mechanisms may play a role in the tumor suppressor activity of APC remains to be determined. It is obvious that the classical paradigms obtained for folded proteins fail to explain the phenotype of APC cancer mutations. We consider it likely that the effect is related to the dynamic nature of the disordered regions of APC. In that respect the recent discovery of the conserved sequence B as a critical functional APC unit is of interest. Obviously, sequence B activity may involve binding partners that remain to be discovered. Alternatively, alterations in sequence B may simply disturb the dynamic interplay of the β-catenin binding repeats or modulate the competition with Axin for β-catenin binding. The importance of disordered regions is a newly emerging field, and its unusually large disordered stretch make APC a key paradigm to understand the role of unfolded regions in general.
Conclusions and perspectives
Current mechanistic models of APC tumor suppressor function leave many questions as to how APC coordinates β-catenin degradation. Through its various domains, APC is able to interact with many different proteins. Multiple repeat regions for interaction with both β-catenin and Axin are implicated in its tumor suppressor activity. Structural information about how these proteins are positioned within the β-catenin destruction complex is lacking. Remarkably, the large central domain of APC, spanning over 2000 amino acids and carrying the repeat regions involved in β-catenin downregulation, is predicted to be entirely unstructured. This feature is rather unique in the human genome as only a few other proteins in the human proteome carry similarly sized unfolded domains. Combined structural and functional analysis of the unstructured domains of APC will be needed to reveal if structure is acquired upon binding to partner proteins. Answers as to how APC missense mutations contribute to tumorigenesis remains to be uncovered by studying how selected tumor-associated mutations interfere with essential tumor suppression mechanisms of APC.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
MM drafted and wrote the manuscript. SR contributed to writing of the manuscript and the generation of essential concepts. Both MM and SR supervised the project. MM, SR and DM generated the figures and contributed to the development of the concepts. DM and MM generated Table S1. ZA and DM collected and summarized essential literature and revised the manuscript critically for important and intellectual content. All authors read and approved the final manuscript.
References 71
- 1.
McCartney BM Nathke IS Cell regulation by the Apc protein Apc as master regulator of epitheliaCurr Opin Cell Biol2008 20186193
Not in our library10.1016/j.ceb.2008.02.001
- 2.
Logan CY Nusse R The Wnt signaling pathway in development and diseaseAnnu Rev Cell Dev Biol2004 20781810
Not in our library10.1146/annurev.cellbio.20.010403.113126
- 3.
Clevers H Wnt/beta-catenin signaling in development and diseaseCell2006 127469480
Not in our library10.1016/j.cell.2006.10.018
- 4.
Aoki K Taketo MM Adenomatous polyposis coli (APC): a multi-functional tumor suppressor geneJ Cell Sci2007 12033273335
Not in our library10.1242/jcs.03485
- 5.
Okada K Bartolini F Deaconescu AM Moseley JB Dogic Z Grigorieff N Gundersen GG Goode BL Adenomatous polyposis coli protein nucleates actin assembly and synergizes with the formin mDia1J Cell Biol2010 18910871096
Not in our library10.1083/jcb.201001016
- 6.
Ishikawa TO Tamai Y Li Q Oshima M Taketo MM Requirement for tumor suppressor Apc in the morphogenesis of anterior and ventral mouse embryoDev Biol2003 253230246
Not in our library10.1016/s0012-1606(02)00020-9
- 7.
Moser AR Shoemaker AR Connelly CS Clipson L Gould KA Luongo C Dove WF Siggers PH Gardner RL Homozygosity for the Min allele of Apc results in disruption of mouse development prior to gastrulationDev Dyn1995 203422433
Not in our library10.1002/aja.1002030405
- 8.
Oshima M Oshima H Kitagawa K Kobayashi M Itakura C Taketo M Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc geneProc Natl Acad Sci USA1995 9244824486
Not in our library10.1073/pnas.92.10.4482
- 9.
Rubinfeld B Albert I Porfiri E Munemitsu S Polakis P Loss of beta-catenin regulation by the APC tumor suppressor protein correlates with loss of structure due to common somatic mutations of the geneCancer Res1997 5746244630
Not in our library
- 10.
Munemitsu S Albert I Souza B Rubinfeld B Polakis P Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor proteinProc Natl Acad Sci USA1995 9230463050
Not in our library10.1073/pnas.92.7.3046
- 11.
Rubinfeld B Souza B Albert I Muller O Chamberlain SH Masiarz FR Munemitsu S Polakis P Association of the APC gene product with beta-cateninScience1993 26217311734
Not in our library10.1126/science.8259518
- 12.
Su LK Vogelstein B Kinzler KW Association of the APC tumor suppressor protein with cateninsScience1993 26217341737
Not in our library10.1126/science.8259519
- 13.
Eklof Spink K Fridman SG Weis WI Molecular mechanisms of beta-catenin recognition by adenomatous polyposis coli revealed by the structure of an APC-beta-catenin complexEMBO J2001 2062036212
Not in our library10.1093/emboj/20.22.6203
- 14.
Hamada F Bienz M The APC tumor suppressor binds to C-terminal binding protein to divert nuclear beta-catenin from TCFDev Cell2004 7677685
Not in our library10.1016/j.devcel.2004.08.022
- 15.
Sierra J Yoshida T Joazeiro CA Jones KA The APC tumor suppressor counteracts beta-catenin activation and H3K4 methylation at Wnt target genesGenes Dev2006 20586600
Not in our library10.1101/gad.1385806
- 16.
Schneikert J Brauburger K Behrens J APC mutations in colorectal tumours from FAP patients are selected for CtBP-mediated oligomerization of truncated APCHum Mol Genet2011
Not in our library10.1093/hmg/ddr273
- 17.
Behrens J Jerchow BA Wurtele M Grimm J Asbrand C Wirtz R Kuhl M Wedlich D Birchmeier W Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3 betaScience1998 280596599
Not in our library10.1126/science.280.5363.596
- 18.
Kishida S Yamamoto H Ikeda S Kishida M Sakamoto I Koyama S Kikuchi A Axin, a negative regulator of the wnt signaling pathway, directly interacts with adenomatous polyposis coli and regulates the stabilization of beta-cateninJ Biol Chem1998 2731082310826
Not in our library10.1074/jbc.273.18.10823
- 19.
Nakamura T Hamada F Ishidate T Anai K Kawahara K Toyoshima K Akiyama T Axin, an inhibitor of the Wnt signalling pathway, interacts with beta-catenin, GSK-3 beta and APC and reduces the beta-catenin levelGenes Cells1998 3395403
Not in our library10.1046/j.1365-2443.1998.00198.x
- 20.
Xing Y Clements WK Le Trong I Hinds TR Stenkamp R Kimelman D Xu W Crystal structure of a beta-catenin/APC complex reveals a critical role for APC phosphorylation in APC functionMol Cell2004 15523533
Not in our library10.1016/j.molcel.2004.08.001
- 21.
Ha NC Tonozuka T Stamos JL Choi HJ Weis WI Mechanism of phosphorylation-dependent binding of APC to beta-catenin and its role in beta-catenin degradationMol Cell2004 15511521
Not in our library10.1016/j.molcel.2004.08.010
- 22.
Graham TA Weaver C Mao F Kimelman D Xu W Crystal structure of a beta-catenin/Tcf complexCell2000 103885896
Not in our library10.1016/s0092-8674(00)00192-6
- 23.
Huber AH Weis WI The structure of the beta-catenin/E-cadherin complex and the molecular basis of diverse ligand recognition by beta-cateninCell2001 105391402
Not in our library10.1016/s0092-8674(01)00330-0
- 24.
Liu J Xing Y Hinds TR Zheng J Xu W The Third 20 Amino Acid Repeat Is the Tightest Binding Site of APC for β-CateninJournal of Molecular Biology2006 360133144
Not in our library10.1016/j.jmb.2006.04.064
- 25.
Xing Y Clements WK Kimelman D Xu W Crystal structure of a β-catenin/Axin complex suggests a mechanism for the β-catenin destruction complexGenes & Development2003 1727532764
Not in our library10.1101/gad.1142603
- 26.
Su Y Fu C Ishikawa S Stella A Kojima M Shitoh K Schreiber EM Day BW Liu B APC is essential for targeting phosphorylated beta-catenin to the SCFbeta-TrCP ubiquitin ligaseMol Cell2008 32652661
Not in our library10.1016/j.molcel.2008.10.023
- 27.
Seo E Jho E-h Axin-independent phosphorylation of APC controls [beta]-catenin signaling via cytoplasmic retention of [beta]-cateninBiochemical and Biophysical Research Communications2007 3578186
Not in our library10.1016/j.bbrc.2007.03.117
- 28.
Roberts DM Pronobis MI Poulton JS Waldmann JD Stephenson EM Hanna S Peifer M Deconstructing the sscatenin destruction complex: mechanistic roles for the tumor suppressor APC in regulating Wnt signalingMol Biol Cell2011 2218451863
Not in our library10.1091/mbc.e10-11-0871
- 29.
Kohler EM Chandra SH Behrens J Schneikert J Beta-catenin degradation mediated by the CID domain of APC provides a model for the selection of APC mutations in colorectal, desmoid and duodenal tumoursHum Mol Genet2009 18213226
Not in our library10.1093/hmg/ddn338
- 30.
Rost B Yachdav G Liu J The PredictProtein serverNucleic Acids Res2004 32W321326
Not in our library10.1093/nar/gkh377
- 31.
Obradovic Z Peng K Vucetic S Radivojac P Dunker AK Exploiting heterogeneous sequence properties improves prediction of protein disorderProteins2005 61Suppl 7176182
Not in our library10.1002/prot.20735
- 32.
Coeytaux K Poupon A Prediction of unfolded segments in a protein sequence based on amino acid compositionBioinformatics2005 2118911900
Not in our library10.1093/bioinformatics/bti266
- 33.
Linding R Russell RB Neduva V Gibson TJ GlobPlot: Exploring protein sequences for globularity and disorderNucleic Acids Res2003 3137013708
Not in our library10.1093/nar/gkg519
- 34.
Prilusky J Felder CE Zeev-Ben-Mordehai T Rydberg EH Man O Beckmann JS Silman I Sussman JL FoldIndex: a simple tool to predict whether a given protein sequence is intrinsically unfoldedBioinformatics2005 2134353438
Not in our library10.1093/bioinformatics/bti537
- 35.
Yang ZR Thomson R McNeil P Esnouf RM RONN: the bio-basis function neural network technique applied to the detection of natively disordered regions in proteinsBioinformatics2005 2133693376
Not in our library10.1093/bioinformatics/bti534
- 36.
Xing Y Takemaru K Liu J Berndt JD Zheng JJ Moon RT Xu W Crystal structure of a full-length beta-cateninStructure2008 16478487
Not in our library10.1016/j.str.2007.12.021
- 37.
Noutsou M Duarte AM Anvarian Z Didenko T Minde DP Kuper I de Ridder I Oikonomou C Friedler A Boelens R Rüdiger SG Maurice MM Critical Scaffolding Regions of the Tumor Suppressor Axin1 Are Natively UnfoldedJ Mol Biol2010
Not in our library10.1016/j.jmb.2010.11.013
- 38.
Li Z Nathke IS Tumor-associated NH2-terminal fragments are the most stable part of the adenomatous polyposis coli protein and can be regulated by interactions with COOH-terminal domainsCancer Res2005 6551955204
Not in our library10.1158/0008-5472.can-04-4609
- 39.
Uversky VN Oldfield CJ Dunker AK Intrinsically disordered proteins in human diseases: introducing the D2 conceptAnnu Rev Biophys2008 37215246
Not in our library10.1146/annurev.biophys.37.032807.125924
- 40.
Ward JJ Sodhi JS McGuffin LJ Buxton BF Jones DT Prediction and Functional Analysis of Native Disorder in Proteins from the Three Kingdoms of LifeJournal of Molecular Biology2004 337635645
Not in our library10.1016/j.jmb.2004.02.002
- 41.
Oldfield CJ Cheng Y Cortese MS Brown CJ Uversky VN Dunker AK Comparing and combining predictors of mostly disordered proteinsBiochemistry2005 4419892000
Not in our library10.1021/bi047993o
- 42.
Cortese MS Uversky VN Keith Dunker A Intrinsic disorder in scaffold proteins: Getting more from lessProgress in Biophysics and Molecular Biology2008 9885106
Not in our library10.1016/j.pbiomolbio.2008.05.007
- 43.
Rotem S Katz C Benyamini H Lebendiker M Veprintsev D Rudiger S Danieli T Friedler A The structure and interactions of the proline-rich domain of ASPP2J Biol Chem2008 2831899018999
Not in our library10.1074/jbc.m708717200
- 44.
- 45.
Dahlberg CL Nguyen EZ Goodlett D Kimelman D Interactions between Casein kinase Iepsilon (CKIepsilon) and two substrates from disparate signaling pathways reveal mechanisms for substrate-kinase specificityPLoS ONE2009 4e4766
Not in our library10.1371/journal.pone.0004766
- 46.
Uversky VN Fink AL The chicken-egg scenario of protein folding revisitedFEBS Lett2002 5157983
Not in our library10.1016/s0014-5793(02)02441-9
- 47.
Kohn JE Millett IS Jacob J Zagrovic B Dillon TM Cingel N Dothager RS Seifert S Thiyagarajan P Sosnick TR Hasan MZ Pande VS Ruczinski I Doniach S Plaxco KW Random-coil behavior and the dimensions of chemically unfolded proteinsProc Natl Acad Sci USA2004 1011249112496
Not in our library10.1073/pnas.0403643101
- 48.
Cantor CR Schimmel PR (Eds.)The Behavior of Biological Macromolecules1980
Not in our library
- 49.
Dyson HJ Wright PE Intrinsically unstructured proteins and their functionsNat Rev Mol Cell Biol2005 6197208
Not in our library10.1038/nrm1589
- 50.
Marsh JA Dancheck B Ragusa MJ Allaire M Forman-Kay JD Peti W Structural diversity in free and bound states of intrinsically disordered protein phosphatase 1 regulatorsStructure2010 1810941103
Not in our library10.1016/j.str.2010.05.015
- 51.
Mittag T Kay LE Forman-Kay JD Protein dynamics and conformational disorder in molecular recognitionJ Mol Recognit2010 23105116
Not in our library10.1002/jmr.961
- 52.
Serber Z Ferrell JE Jr Tuning bulk electrostatics to regulate protein functionCell2007 128441444
Not in our library10.1016/j.cell.2007.01.018
- 53.
Spink KE Polakis P Weis WI Structural basis of the Axin-adenomatous polyposis coli interactionEMBO Journal2000 1922702279
Not in our library10.1093/emboj/19.10.2270
- 54.
Keramisanou D Biris N Gelis I Sianidis G Karamanou S Economou A Kalodimos CG Disorder-order folding transitions underlie catalysis in the helicase motor of SecANat Struct Mol Biol2006 13594602
Not in our library10.1038/nsmb1108
- 55.
Bruschweiler S Schanda P Kloiber K Brutscher B Kontaxis G Konrat R Tollinger M Direct Observation of the Dynamic Process Underlying Allosteric Signal TransmissionJ Am Chem Soc2009 13130633068
Not in our library10.1021/ja809947w
- 56.
Segditsas S Tomlinson I Colorectal cancer and genetic alterations in the Wnt pathwayOncogene2006 2575317537
Not in our library10.1038/sj.onc.1210059
- 57.
Groden J Identification and characterization of the familial adenomatous polyposis coli geneCell1991 66589600
Not in our library10.1016/0092-8674(81)90021-0
- 58.
Kinzler KW Nilbert MC Su LK Vogelstein B Bryan TM Levy DB Smith KJ Preisinger AC Hedge P McKechnie D Finniear R Markham A Grotten J Boguski MS Altschul SF Horii A Ando H Miyoshi Y Miki Y Nishisho I Nakamura Y Identification of FAP locus genes from chromosome 5q211991 253661665
Not in our library10.1126/science.1651562
- 59.
Fearnhead NS Winney B Bodmer WF Rare Variant Hypothesis for Multifactorial Inheritance: Susceptibility to Colorectal Adenomas as a ModelCell Cycle2005 4521525
Not in our library10.4161/cc.4.4.1591
- 60.
Kinzler KW Vogelstein B Lessons from hereditary colorectal cancerCell1996 87159170
Not in our library10.1016/s0092-8674(00)81333-1
- 61.
Lamlum H Ilyas M Rowan A Clark S Johnson V Bell J Frayling I Efstathiou J Pack K Payne S Roylance R Gorman P Sheer D Neale K Phillips R Talbot I Bodmer W Tomlinson I The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: a new facet to Knudson's 'two-hit' hypothesisNat Med1999 510711075
Not in our library10.1038/12511
- 62.
Fodde R Smits R Disease model: familial adenomatous polyposisTrends in Molecular Medicine2001 7369373
Not in our library10.1016/s1471-4914(01)02050-0
- 63.
Gaspar C Fodde R APC dosage effects in tumorigenesis and stem cell differentiationInt J Dev Biol2004 48377386
Not in our library10.1387/ijdb.041807cg
- 64.
Bougatef K Ouerhani S Moussa A Kourda N Coulet F Colas C Lahely YB Najjar T Ben Jilani S Benammar-Elgaaied A Soubrier F Marrakchi R Prevalence of mutations in APC, CTNNB1, and BRAF in Tunisian patients with sporadic colorectal cancerCancer Genet Cytogenet2008 1871218
Not in our library10.1016/j.cancergencyto.2008.06.016
- 65.
Kastritis E Murray S Kyriakou F Horti M Tamvakis N Kavantzas N Patsouris ES Noni A Legaki S Dimopoulos MA Bamias A Somatic mutations of adenomatous polyposis coli gene and nuclear b-catenin accumulation have prognostic significance in invasive urothelial carcinomas: evidence for Wnt pathway implicationInt J Cancer2009 124103108
Not in our library10.1002/ijc.23917
- 66.
Azzopardi D Dallosso AR Eliason K Hendrickson BC Jones N Rawstorne E Colley J Moskvina V Frye C Sampson JR Wenstrup R Scholl T Cheadle JP Multiple Rare Nonsynonymous Variants in the Adenomatous Polyposis Coli Gene Predispose to Colorectal Adenomas2008 68358363
Not in our library10.1158/0008-5472.can-07-5733
- 67.
Nimura Y Furuwatari C Fujimori M Fujimori Y Nakata S Ito K Hama Y Shingu K Adachi W Ogiso Y Furihata K Katsuyama T Amano J Germline mutations of the APC gene in two Japanese adenomatous polyposis patientsJpn J Hum Genet1997 42433439
Not in our library10.1007/bf02766945
- 68.
Munoz V Serrano L Helix design, prediction and stabilityCurr Opin Biotechnol1995 6382386
Not in our library10.1016/0958-1669(95)80066-2
- 69.
Ferrarese A Marin O Bustos VH Venerando A Antonelli M Allende JE Pinna LA Chemical dissection of the APC Repeat 3 multistep phosphorylation by the concerted action of protein kinases CK1 and GSK3Biochemistry2007 461190211910
Not in our library10.1021/bi701674z
- 70.
Sugase K Dyson HJ Wright PE Mechanism of coupled folding and binding of an intrinsically disordered proteinNature2007 44710211025
Not in our library10.1038/nature05858
- 71.
Tsai CJ Del Sol A Nussinov R Protein allostery, signal transmission and dynamics: a classification scheme of allosteric mechanismsMol Biosyst2009 5207216
Not in our library10.1039/b819720b
Cited by papers we hold 5
- Regulating tumor suppressor genes: post-translational modifications · 2020No notice
- CircMYO10 promotes osteosarcoma progression by regulating miR-370-3p/RUVBL1 axis to enhance the transcriptional activity of β-catenin/LEF1 complex via effects on chromatin remodeling · 2019Corrected
- WNT Signaling in Disease · 2019No notice
- Regulation of Wnt/β‐catenin signalling by tankyrase‐dependent poly(ADP‐ribosyl)ation and scaffolding · 2017No notice
- Determining biophysical protein stability in lysates by a fast proteolysis assay, FASTpp. · 2012Not checked
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.